Lakeside Holding Limited Stock Price, News & Analysis

Lakeside Holding (Nasdaq: LSH), a U.S.-based cross-border supply chain solution provider focused on Asia-Pacific, has secured a convertible debt financing agreement worth up to $4.5 million through senior secured 7% original issue discount convertible promissory notes with 40% warrant coverage.

The initial tranche closed on March 5, 2025, with the company selling a $1 million note and warrants for 318,827 shares at an exercise price of $1.9098, generating gross proceeds of $930,000. The financing will be drawn in tranches, potentially yielding total gross proceeds of approximately $4.2 million, which the company intends to use for working capital purposes.

Lakeside Holding (LSH) reported financial results for Q2 FY2025. Total revenues decreased by 31.3% to $3.4M for Q2, primarily due to reduced cross-border airfreight volumes. The company reported a gross loss of $42,231 in Q2 FY2025, compared to a gross profit of $1.1M in Q2 FY2024.

Key operational highlights include expansion of Dallas-Fort Worth facilities from 20,000 to 46,657 square feet, acquisition of Hupan Pharmaceutical for RMB 4.0M ($0.6M), and new partnerships with major e-commerce platforms. Revenues from Asia-based customers grew 29.4% in H1 FY2025, while U.S.-based customer revenues declined 60.2%.

The company reported a net loss of $1.9M for Q2 FY2025, compared to net income of $0.06M in Q2 FY2024. For H1 FY2025, net loss was $3.3M versus $0.2M loss in H1 FY2024.

Lakeside Holding (Nasdaq: LSH) announced that its subsidiary, Hupan Pharmaceutical, has secured two distribution agreements with Hubei Kelun Pharmaceutical Trading Co., , a subsidiary of Sichuan Kelun Pharmaceutical Co. (002422.SZ). The agreements, effective from January 1, 2025, to December 31, 2025, enable Hupan Pharmaceutical to distribute large-volume parenteral solutions and related medical products to healthcare institutions across China.

This development follows Lakeside's recent agreement with Sichuan Huiyu Pharmaceutical, a specialist in oncology and immune-related therapies, demonstrating the company's growing presence in the pharmaceutical distribution sector. The new partnerships reinforce Hupan Pharmaceutical's ability to establish relationships with major pharmaceutical companies in the industry.

Lakeside Holding (Nasdaq: LSH) has announced that Hupan Pharmaceutical has entered into a strategic distribution agreement with Huiyu Pharmaceutical (Shanghai: 688553.SS). Under the agreement, Hupan Pharmaceutical will distribute Huiyu's oncology and immunotherapy drugs to healthcare institutions in domestic and global markets.

Huiyu Pharmaceutical's flagship product, Pemetrexed Disodium for Injection, has received regulatory approvals in major markets including China, the UK, Germany, and Finland. The product is recognized for treating non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma.

The partnership aims to expand the reach of Huiyu's innovative oncology solutions and deliver life-saving treatments to broader markets through Lakeside's healthcare distribution capabilities.

Lakeside Holding (Nasdaq: LSH) has announced that its subsidiary Hupan Pharmaceutical signed a $1.5 million sales agreement with Sinopharm Holding Hubei New Special Medicine, a subsidiary of Sinopharm Group. The agreement, effective from January 1, 2025, through year-end, covers the delivery of critical medicines including Sodium Bicarbonate, Glucose, and Glucose Sodium Chloride.

This agreement follows a previous partnership with Sinopharm Group focused on medicine storage, transportation, and logistics services, strengthening Hupan Pharmaceutical's position as a pharmaceutical solutions provider in China.

Lakeside Holding (Nasdaq: LSH), a U.S.-based integrated cross-border supply chain solution provider, announced its participation in The Benchmark Company's 13th Annual Discovery One-on-One Investor Conference. The event will take place on December 11th, 2024 at the New York Athletic Club in New York City. CEO Henry Liu will conduct one-on-one meetings with investors and analysts throughout the day. The conference provides emerging growth and dynamic publicly traded companies with opportunities to connect with institutional and individual investors in a unique one-on-one format.

Lakeside Holding (Nasdaq: LSH) announces that its recently acquired subsidiary, Hupan Pharmaceutical, has established a partnership with Sinopharm Group Hubei for pharmaceutical logistics services. The partnership covers essential medicine storage, transportation, and logistics services, including handling refrigerated medications, peptide hormones, and medical supplies. Hupan Pharmaceutical is expected to contribute approximately $7 million in annual revenues to Lakeside. The collaboration strengthens Lakeside's position in China's healthcare market and expands its pharmaceutical logistics capabilities.

Lakeside Holding (LSH) reported Q1 FY2025 results with total revenues decreasing 1.6% to $4.08M from $4.15M in Q1 FY2024. The company saw mixed performance across segments, with cross-border airfreight solutions declining 8.2% to $2.2M, while ocean freight solutions grew 7.8% to $1.8M. Revenue from Asia-based customers surged 65.8% to $2.8M, while U.S.-based customer revenue fell 48.2% to $1.3M. The company reported a net loss of $1.3M compared to $0.3M in the same period last year, with gross margin declining to 12.8% from 15.6%.

Lakeside Holding (Nasdaq: LSH), a U.S.-based cross-border supply chain solution provider, has acquired Hupan Pharmaceutical (Hubei) Co., through its subsidiary Sichuan Hupan Jincheng Enterprise Management Co., The acquisition, valued at RMB 4.0 million (US$0.6 million), is expected to add approximately US$7 million in annual revenue to Lakeside. Hupan Pharmaceutical, founded in May 2024 and headquartered in Wuhan, specializes in pharmaceutical distribution and supply chain services, including refrigerated and frozen pharmaceuticals, peptide hormones, and other critical medications. The company holds licenses for drug wholesale, retail, and third-class medical device distribution in China. Hupan Pharmaceutical has partnerships with leading pharmaceutical manufacturers and regional healthcare institutions, including 15 major hospitals in Wuhan. This acquisition strengthens Lakeside's capabilities in the medical logistics sector in China.